RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Heidelberg Pharma - Stock

Heidelberg Pharma Revenue 2024

Heidelberg Pharma Revenue

11.25 M EUR

Ticker

HPHA.DE

ISIN

DE000A11QVV0

WKN

A11QVV

In 2024, Heidelberg Pharma's sales reached 11.25 M EUR, a 14.15% difference from the 9.86 M EUR sales recorded in the previous year.

The Heidelberg Pharma Revenue history

YEARREVENUE (undefined EUR)GROSS MARGIN (%)
2026e36.0818,31
2025e15.343,18
2024e11.2558,70
20239.8667,01
202218.5174,73
20211.75-169,29
20208.4934,03
20197.3148,85
20183.6739,80
20171.949,65
20161.3640,60
20152.2850,09

Heidelberg Pharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Heidelberg Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Heidelberg Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Heidelberg Pharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Heidelberg Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Heidelberg Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Heidelberg Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Heidelberg Pharma’s growth potential.

Heidelberg Pharma Revenue, Profit, and EBIT History

DateHeidelberg Pharma RevenueHeidelberg Pharma EBITHeidelberg Pharma Net Income
2026e36.08 M undefined-17.69 M undefined-38.18 M undefined
2025e15.3 M undefined-11.83 M undefined-6.18 M undefined
2024e11.25 M undefined-27.71 M undefined-29.95 M undefined
20239.86 M undefined-21.3 M undefined-20.35 M undefined
202218.51 M undefined-18.26 M undefined-19.7 M undefined
20211.75 M undefined-25.93 M undefined-26.14 M undefined
20208.49 M undefined-18.52 M undefined-18.37 M undefined
20197.31 M undefined-10.37 M undefined-10.15 M undefined
20183.67 M undefined-11.94 M undefined-11.67 M undefined
20171.9 M undefined-10.86 M undefined-10.97 M undefined
20161.36 M undefined-6.58 M undefined-6.39 M undefined
20152.28 M undefined-6.6 M undefined-6.55 M undefined

Heidelberg Pharma stock margins

The Heidelberg Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Heidelberg Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Heidelberg Pharma.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Heidelberg Pharma's sales revenue. A higher gross margin percentage indicates that the Heidelberg Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Heidelberg Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Heidelberg Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Heidelberg Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Heidelberg Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Heidelberg Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Heidelberg Pharma Margin History

Heidelberg Pharma Gross marginHeidelberg Pharma Profit marginHeidelberg Pharma EBIT marginHeidelberg Pharma Profit margin
2026e67.01 %-49.04 %-105.83 %
2025e67.01 %-77.33 %-40.39 %
2024e67.01 %-246.22 %-266.09 %
202367.01 %-216.07 %-206.38 %
202274.73 %-98.63 %-106.42 %
2021-169.29 %-1,482.09 %-1,493.79 %
202034.03 %-218.14 %-216.41 %
201948.85 %-141.83 %-138.84 %
201839.8 %-325.67 %-318.23 %
201749.65 %-571.78 %-577.33 %
201640.6 %-483.14 %-469.04 %
201550.09 %-288.79 %-286.87 %

Heidelberg Pharma Aktienanalyse

What does Heidelberg Pharma do?

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. The company was founded in 1998 and currently employs about 100 employees. Heidelberg Pharma's business model focuses on discovering and developing novel cancer therapies based on antibody-drug conjugates (ADCs). The foundation of Heidelberg Pharma's work lies in research and development in the field of cancer immunotherapy. The company has invested a lot in recent years to develop a wide range of ADCs and test them in clinical trials. The goal of the company is to develop novel therapies that can be used in the fight against cancer. Heidelberg Pharma has three different divisions: the research and development department, the subsidiary Heidelberg Pharma Research GmbH, and the subsidiary Heidelberg Pharma Development GmbH. The research and development department works on innovative technologies and drugs to combat cancer. Both established and novel approaches are used to achieve high efficacy while maintaining tolerability. The subsidiary Heidelberg Pharma Research GmbH is dedicated to developing new ADC therapy approaches, particularly in collaboration with partners. This includes the production and quality control of ADCs as well as the conduct of preclinical studies. On the other hand, the subsidiary Heidelberg Pharma Development GmbH specializes in clinical development and is responsible for the preparation and conduct of clinical trials. Heidelberg Pharma's products mainly include cancer therapies based on ADCs. One such ADC is the product HDP-101, which is currently in Phase I clinical trials. The drug is a better-tolerated successor to the well-known drug doxorubicin, which targets the tumor in combination with a specific antibody. The aim is to effectively destroy the tumor without damaging the healthy cells in the body. Another product in Heidelberg Pharma's pipeline is the ADC HDP-102, which is also being tested in Phase I clinical trials. This is a treatment option specifically intended for the malignant blood disorder multiple myeloma. In addition to developing its own products, Heidelberg Pharma also collaborates closely with partners to develop innovative ADCs. The goal is to provide new therapies as quickly as possible and thus win the fight against cancer. In recent years, Heidelberg Pharma AG has made significant progress and established itself as one of the leading biotechnology companies in the field of cancer research. The company places special emphasis on quality, efficiency, and innovation. Based on its experiences and progress, Heidelberg Pharma plans to remain a leader in the field of cancer research and therapies and further strengthen its position in the industry. Heidelberg Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Heidelberg Pharma's Sales Figures

The sales figures of Heidelberg Pharma originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Heidelberg Pharma’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Heidelberg Pharma's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Heidelberg Pharma’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Heidelberg Pharma Stock

How much revenue did Heidelberg Pharma generate this year?

Heidelberg Pharma has achieved a revenue of 11.25 M EUR this year.

How much was the turnover of the company Heidelberg Pharma compared to the previous year?

The revenue of Heidelberg Pharma has increased by 14.15% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Heidelberg Pharma?

The revenue of Heidelberg Pharma is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Heidelberg Pharma measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Heidelberg Pharma so important for investors?

The revenue of Heidelberg Pharma is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Heidelberg Pharma pay?

Over the past 12 months, Heidelberg Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Heidelberg Pharma is expected to pay a dividend of 0 EUR.

What is the dividend yield of Heidelberg Pharma?

The current dividend yield of Heidelberg Pharma is .

When does Heidelberg Pharma pay dividends?

Heidelberg Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Heidelberg Pharma?

Heidelberg Pharma paid dividends every year for the past 0 years.

What is the dividend of Heidelberg Pharma?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Heidelberg Pharma located?

Heidelberg Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Heidelberg Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Heidelberg Pharma from 6/26/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 6/26/2024.

When did Heidelberg Pharma pay the last dividend?

The last dividend was paid out on 6/26/2024.

What was the dividend of Heidelberg Pharma in the year 2023?

In the year 2023, Heidelberg Pharma distributed 0 EUR as dividends.

In which currency does Heidelberg Pharma pay out the dividend?

The dividends of Heidelberg Pharma are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Heidelberg Pharma stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Heidelberg Pharma

Our stock analysis for Heidelberg Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Heidelberg Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.